AG-236
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-05 — A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera: Phase 2/3 placebo-controlled trial in adults with PV launched to evaluate AG-236 for increasing the proportion of patients free of phlebotomy and phlebotomy eligibility over a 13-week primary assessment period, with a dose-finding stage and open-label extension; no efficacy or safety results reported yet (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
05-oct-2026
novelty 3
per-area 3
introduces